Evaluating Clinical Impact of Linear Energy Transfer Distribution in Proton Therapy for Primary Brain Tumours (LET-PT)
Evaluating Clinical Impact of Linear Energy Transfer Distribution in Proton Therapy for Primary Brain Tumours - a Prospective Study
The goal of this prospective study is to evaluate whether incorporating linear energy transfer (LET) and variable relative biological effectiveness (RBE) into proton therapy (PT) treatment planning is feasible and may reduce treatment-related adverse events in patients with primary brain tumours. For all participants, the LET distribution and the McNamara variable RBE model will be evaluated during treatment planning. Where feasible, the proton therapy plan will be optimised to reduce areas of high LET in healthy brain tissue while maintaining adequate treatment of the tumour. Participants will undergo standard clinical and MRI follow-up and will additionally be asked to complete quality-of-life questionnaires at several time points.
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
Szczegółowy opis
In clinical treatment planning, a constant RBE of 1.1 is assumed. However, proton RBE depends on several factors, including linear energy transfer (LET). RBE uncertainties can result in unexpected toxicities in patients treated with proton therapy (PT) for primary brain tumours. To address RBE uncertainties in PT treatment planning, this prospective trial evaluates the feasibility and outcomes of incorporating LET distribution information and the McNamara variable RBE model into treatment planning for patients diagnosed with primary brain tumours. The primary objective is to evaluate the effect of this planning strategy on the incidence of treatment-related imaging abnormalities (TRIA) in healthy brain tissue after PT. Outcomes will be compared with those of a historical cohort of patients who received PT at the same centre before the introduction of the novel planning strategy.
Secondary objectives are:
- To gain further insight into the feasibility of an LET-based treatment planning method in primary brain tumours.
- To assess additional side effects after PT for primary brain tumours.
- To investigate the response of primary brain tumours after PT.
Participants will undergo standard clinical and MRI follow-up and will complete quality-of-life questionnaires at predefined time points.
Typ studiów
Typ studiów
Zapisy (Szacowany)
Zapisy
Faza
Faza
- Nie dotyczy
Kontakty i lokalizacje
Kontakt w sprawie studiów
Kontakt w sprawie studiów
- Nazwa: Lieselotte Lauwens, MD
- Numer telefonu: +32 16 34 76 00
- E-mail: lieselotte.lauwens@uzleuven.be
Kopia zapasowa kontaktu do badania
- Nazwa: Maarten Lambrecht, MD PhD
- Numer telefonu: +32 16 34 76 00
- E-mail: maarten.lambrecht@uzleuven.be
Lokalizacje studiów
-
-
-
Leuven, Belgia
- UZ Leuven
-
Kontakt:
- Maarten Lambrecht, MD PhD
- Numer telefonu: +32 16 34 76 00
- E-mail: maarten.lambrecht@uzleuven.be
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
- Dziecko
- Dorosły
- Starszy dorosły
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
-
Patients diagnosed with primary brain tumours including, but not limited to:
- Low-grade glioma including: paediatric-type diffuse low-grade glioma, astrocytoma, IDH-mutant and oligodendroglioma, IDH-mutant and 1p/19q-codeleted
- Ependymal tumours
- Tumours of the sellar region including, but not limited to, craniopharyngioma
- Medulloblastoma and other embryonal tumours, including, but not limited to, atypical teratoid/rhabdoid tumours
- Meningioma
- Primary neuroectodermal tumours
- Germ cell tumours
- Choroid plexus tumours
- Pineal tumours
-
Both adults and children are eligible for inclusion
-
Referred to PARTICLE for proton therapy treatment
-
Treatment with PT approved and reimbursed by RIZIV/INAMI
-
Ability of patient and/or parents or legal guardian to sign informed consent
Exclusion Criteria:
- Mixed photon-proton planning
- Re-irradiation
- Contraindication for MRI (claustrophobia, metallic implants like pacemaker/ICD/neurostimulator)
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Nie dotyczy
- Model interwencyjny: Zadanie dla jednej grupy
- Maskowanie: Brak (otwarta etykieta)
Liczba ramion
Broń i interwencje
Grupa uczestników / ArmGrupa uczestników / Arm |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
Eksperymentalny: LET-based evaluation in treatment planning
|
Treatment planning will initially be performed according to standard clinical practice using an RBE-weighted dose based on a fixed RBE of 1.1, expressed in Gy(RBE). The resulting plan will then undergo additional evaluation using LET distributions and variable RBE-weighted dose distributions calculated with the McNamara model. If areas of high LET or high estimated biological dose are identified in healthy brain tissue, the treatment plan may be adjusted to reduce these areas while maintaining adequate target coverage and compliance with standard dose constraints for organs at risk. LET and variable RBE evaluation will be used as auxiliary planning metrics and will not replace standard clinical dose evaluation.
Inne nazwy:
MRI assessments according to routine follow-up for TRIA and response assessment. Assessing QoL in adults (aged > 25 years) using the EORTC QLQ-C30 and EORTC QLQ-BN20 questionnaires. Assessing QoL in children (aged ≤ 25 years) using the age-appropriate PedsQL Brain Tumour Module. Evaluating the incidence of CNS toxicities using the CTCAE v5.0 |
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
The occurrence of Treatment-Related Imaging Abnormality (TRIA) CTCAE version 5.0 grade ≥ 1.
Ramy czasowe: Up to 12 months after treatment. MRI at 6 and 12 months after completion of proton therapy treatment for assessment of TRIA.
|
TRIA is defined as any new or increased abnormality observed on post-contrast T1-weighted, T2-weighted, or T2-weighted-FLAIR MRI sequences, absent on the corresponding pre-radiotherapy (and post-surgical, if surgery preceded radiotherapy) imaging, not consistent with post-surgical changes or unambiguous tumour progression, with confirmation on subsequent follow-up MRI recommended to substantiate this diagnosis. TRIA will be scored as a CNS necrosis adverse event according to the CTCAE scale version 5.0. |
Up to 12 months after treatment. MRI at 6 and 12 months after completion of proton therapy treatment for assessment of TRIA.
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Treatment planning feasibility: number of plan iterations.
Ramy czasowe: Baseline (during treatment planning).
|
Evaluating the number of plan iterations required for a satisfactory LET-based treatment plan, acting as a surrogate for additional planning time required in the treatment planning workflow. |
Baseline (during treatment planning).
|
|
Treatment planning feasibility: number of plans requiring LET-based replanning.
Ramy czasowe: Baseline (during treatment planning).
|
Evaluating the number of RBE1.1-based plans in need of a replanning to a LET-based treatment plan. |
Baseline (during treatment planning).
|
|
Treatment planning feasibility: planning effort
Ramy czasowe: Baseline (once before and once after LET-based replanning).
|
Evaluating the effort needed for replanning using the National Aeronautics and Space Administration Task Load Index (NASA-TLX). Workload is rated on six subscales (mental demand, physical demand, temporal demand, performance, effort and frustration), each scored from 0 to 20; the overall score is the mean of the six subscales (0-20). Higher scores indicate a higher workload (worse outcome). |
Baseline (once before and once after LET-based replanning).
|
|
CNS toxicities
Ramy czasowe: Baseline; during proton therapy in weeks 1, 2, 3, 4, 5 and 6; and at 3, 6, 9 and 12 months after proton therapy.
|
Evaluating the incidence of CNS toxicities graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Grades range from 1 (mild) to 5 (death related to adverse event); higher grades indicate a worse outcome. |
Baseline; during proton therapy in weeks 1, 2, 3, 4, 5 and 6; and at 3, 6, 9 and 12 months after proton therapy.
|
|
Quality of life assessments: European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30).
Ramy czasowe: Baseline; at last proton therapy fraction; 6 and 12 months after proton therapy.
|
Assessing QoL in adults (aged > 25 years) using the EORTC QLQ-C30. Scores range from 0 to 100. For the global health status and functional scales, higher scores indicate better quality of life and functioning; for the symptom scales, higher scores indicate a higher symptom burden (worse outcome). |
Baseline; at last proton therapy fraction; 6 and 12 months after proton therapy.
|
|
Quality of life assessments: European Organisation for Research and Treatment of Cancer - Quality of Life Questionnaire - Brain Neoplasm (20 items) (EORTC QLQ-BN20).
Ramy czasowe: Baseline; at last proton therapy fraction; 6 and 12 months after proton therapy.
|
Assessing QoL in adults (aged >25 years) using the EORTC QLQ-BN20. Scores range from 0 to 100; higher scores indicate a higher symptom burden (worse outcome). |
Baseline; at last proton therapy fraction; 6 and 12 months after proton therapy.
|
|
Quality of life assessments: Pediatric Quality of Life Inventory (PedsQL) Brain Tumor Module.
Ramy czasowe: Baseline; at last proton therapy fraction; 6 and 12 months after proton therapy.
|
Assessing QoL in children (aged ≤ 25 years) using the age-appropriate PedsQL Brain Tumor Module. Scores range from 0 to 100; higher scores indicate better health-related quality of life. |
Baseline; at last proton therapy fraction; 6 and 12 months after proton therapy.
|
|
Response assessment
Ramy czasowe: At 6 and 12 months after proton therapy.
|
Number of participants per response category (complete response, partial response, stable disease, progressive disease) according to the Response Assessment in Neuro-Oncology (RANO) criteria. |
At 6 and 12 months after proton therapy.
|
|
Comparing RBE1.1-based PT plan and a LET-based treatment plan: Maximum LETd in healthy brain tissue.
Ramy czasowe: Baseline (after treatment planning).
|
Comparing the maximum dose-averaged linear energy transfer (LETd), reported as D1% (in keV/µm), in healthy brain tissue between the RBE1.1-based plan and the LET-based plan. |
Baseline (after treatment planning).
|
|
Comparing RBE1.1-based PT plan and a LET-based treatment plan: Maximum constant RBE-weighted dose in healthy brain tissue.
Ramy czasowe: Baseline (after treatment planning).
|
Comparing the maximum constant RBE-weighted dose (RBE 1.1), reported as D0.03cc (in Gy(RBE)), in healthy brain tissue between the RBE1.1-based plan and the LET-based plan. |
Baseline (after treatment planning).
|
|
Comparing RBE1.1-based PT plan and a LET-based treatment plan: Maximum variable RBE-weighted dose in healthy brain tissue.
Ramy czasowe: Baseline (after treatment planning).
|
Comparing the maximum McNamara variable RBE-weighted dose, reported as D0.03cc (in Gy(RBE)), in healthy brain tissue between the RBE1.1-based plan and the LET-based plan. |
Baseline (after treatment planning).
|
|
Comparing RBE1.1-based PT plan and a LET-based treatment plan: Target coverage.
Ramy czasowe: Baseline (after treatment planning).
|
Comparing target coverage, reported as [CTV D98%] (in Gy(RBE)), between the RBE1.1-based plan and the LET-based plan. |
Baseline (after treatment planning).
|
Współpracownicy i badacze
Sponsor
Sponsor
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Szacowany)
Rozpoczęcie studiów
Zakończenie podstawowe (Szacowany)
Zakończenie podstawowe
Ukończenie studiów (Szacowany)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Choroby mózgu
- Choroby ośrodkowego układu nerwowego
- Choroby Układu Nerwowego
- Nowotwory według lokalizacji
- Nowotwory
- Nowotwory Układu Nerwowego
- Nowotwory ośrodkowego układu nerwowego
- Nowotwory mózgu
- Lecznictwo
- Zdrowie publiczne
- Środowisko i zdrowie publiczne
- Status zdrowotny
- Demografia
- Pomiary epidemiologiczne
- Ciężka radioterapia jonowa
- Radioterapia
- Jakość życia
- Terapia protonowa
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- S71405
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .